Ixazomib–Thalidomide–Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma

被引：0

作者：

Heinz Ludwig

Wolfram Poenisch

Stefan Knop

Alexander Egle

Martin Schreder

Daniel Lechner

Roman Hajek

Eberhard Gunsilius

Karl Jochen Krenosz

Andreas Petzer

Katja Weisel

Dietger Niederwieser

Hermann Einsele

Wolfgang Willenbacher

Thomas Melchardt

Richard Greil

Niklas Zojer

机构：

[1] Center for Oncology and Hematology,Wilhelminen Cancer Research Institute, Department of Medicine I

[2] University of Leipzig,Department of Hematology

[3] Wuerzburg University Medical Center,Division of Hematology and Medical Oncology, Department of Internal Medicine II

[4] Paracelsus Medical University,Department of Internal Medicine III with Haematology, Medical Oncology, Hemostaseology, Infectiology and Rheumatology, Oncologic Center, Salzburg Cancer Research Institute—Laboratory for Immunological and Molecular Cancer Rese

[5] Center for Oncology and Hematology,LIMCR)

[6] Department of Medicine I—Hematology with Stem Cell Transplantation,Department of Medicine I

[7] Hemostaseology and Medical Oncology,Department of Internal Medicine V, Hematology and Oncology

[8] Ordensklinikum Linz Elisabethinen,Department of Internal Medicine 3

[9] Fakultní Nemocnice Ostrava,undefined

[10] Medical University Innsbruck,undefined

[11] Kepler Universitaetsklinikum GmbH,undefined

[12] Med Campus III,undefined

[13] Department of Internal Medicine I,undefined

[14] Ordensklinikum Linz—Barmherzige Schwestern,undefined

[15] University Medical Center of Hamburg-Eppendorf,undefined

[16] Hamburg,undefined

[17] Germany and University of Tuebingen,undefined

[18] Oncotyrol,undefined

[19] Center for personalized Cancer Medicine,undefined

来源：

British Journal of Cancer | 2019年 / 121卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：751 / 757

页数：6

共 50 条

[1] Ixazomib-Thalidomide-Dexamethasone for induction therapy followed by Ixazomib maintenance treatment in patients with relapsed/refractory multiple myeloma
Ludwig, Heinz
Poenisch, Wolfram
Knop, Stefan
Egle, Alexander
Schreder, Martin
Lechner, Daniel
Hajek, Roman
Gunsilius, Eberhard
Krenosz, Karl Jochen
Petzer, Andreas
Weisel, Katja
Niederwieser, Dietger
Einsele, Hermann
Willenbacher, Wolfgang
Melchardt, Thomas
Greil, Richard
Zojer, Niklas
[J]. BRITISH JOURNAL OF CANCER, 2019, 121 (09) : 751 - 757
[2] Health-Related Quality of Life in Patients with Relapsed/Refractory Multiple Myeloma during Treatment with Ixazomib-Thalidomide-Dexamethasone Followed By Ixazomib Maintenance
Ludwig, Heinz
Ponisch, Wolfram
Egle, Alexander
Knop, Stefan
Schreder, Martin
Lechner, Daniel
Hajek, Roman
Gunsilius, Eberhard
Fridrik, Michael A.
Petzer, Andreas
Weisel, Katja C.
Niederwieser, Dietger
Hinke, Axel
Greil, Richard
Zojer, Niklas
[J]. BLOOD, 2017, 130
[3] Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population
Ludwig, Heinz
Poenisch, Wolfram
Knop, Stefan
Egle, Alexander
Hinke, Axel
Schreder, Martin
Lechner, Daniel
Hajek, Roman
Gunsilius, Eberhard
Petzer, Andreas
Weisel, Katja
Niederwieser, Dietger
Einsele, Hermann
Willenbacher, Wolfgang
Rumpold, Holger
Pour, Ludek
Jelinek, Tomas
Krenosz, Karl Jochen
Meckl, Angela
Nolte, Sandra
Melchardt, Thomas
Greil, Richard
Zojer, Niklas
[J]. LEUKEMIA & LYMPHOMA, 2020, 61 (02) : 377 - 386
[4] Ixazomib in Combination With Thalidomide and Dexamethasone as Treatment for Patients With Relapsed/Refractory Multiple Myeloma: An Ongoing Phase II Trial
Ludwig, Heinz
Lechner, Daniel
Gunsilius, Eberhard
Fridrik, Michael
Petzer, Andreas
Kuehr, Thomas
Knop, Stefan
Schreder, Martin
Weisel, Katja
Rauch, Elisabeth
Poenisch, Wolfram
Greil, Richard
Zojer, Niklas
[J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2017, 17 (01): : E75 - E75
[5] REAL WORLD USE OF IXAZOMIB WITH LENALIDOMIDE AND DEXAMETHASONE FOR PATIENTS WITH RELAPSED AND RELAPSED REFRACTORY MULTIPLE MYELOMA
Ziff, M.
Cheesman, S.
Kyriakou, C.
Mehta, A.
Papanikolaou, X.
Rabin, N.
Wechalekar, A.
Yong, K.
Popat, R.
[J]. HAEMATOLOGICA, 2017, 102 : 786 - 787
[6] Ixazomib in Combination with Thalidomide and Dexamethasone for Induction and Ixazomib Maintenance Therapy Overcomes High-Risk Cytogenetics (but not of 1q21 Gain) in Relapsed/Refractory Multiple Myeloma - AGMT_MM1
Ludwig, Heinz
Poenisch, Wolfram
Knop, Stefan
Schreder, Martin
Lechner, Daniel
Hajek, Roman
Gunsilius, Eberhard
Krenosz, Karl Jochen
Petzer, Andreas
Weisel, Katja
Einsele, Hermann
Greil, Richard
Zojer, Niklas
[J]. BLOOD, 2018, 132
[7] Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma
Al-Salama, Zaina T.
Garnock-Jones, Karly P.
Scott, Lesley J.
[J]. TARGETED ONCOLOGY, 2017, 12 (04) : 535 - 542
[8] Ixazomib: A Review in Relapsed and/or Refractory Multiple Myeloma
Zaina T. Al-Salama
Karly P. Garnock-Jones
Lesley J. Scott
[J]. Targeted Oncology, 2017, 12 : 535 - 542
[9] Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
Ohashi, Yasukata
Yatabe, Megumi
Niijima, Daisuke
Tani, Kentaro
Ogawa, Chiaki
Yachi, Yutaka
Kagoo, Toshiya
Boku, Saigen
Ueno, Hironori
Yano, Takahiro
Higai, Koji
Yokoyama, Akihiro
[J]. IN VIVO, 2020, 34 (05): : 2821 - 2828
[10] Ixazomib, Thalidomide and Dexamethasone (IxaThalDex) in Relapsed/Refractory Multiple Myeloma (RRMM): An Interim Analysis of a Phase II Trial
Ludwig, Heinz
Gunsilius, Eberhard
Fridrik, Michael
Greil, Richard
Petzer, Andreas
Kuehr, Thomas
Knop, Stefan
Schreder, Martin
Rauch, Elisabeth
Poenisch, Wolfram
Zojer, Niklas
[J]. BLOOD, 2016, 128 (22)

← 1 2 3 4 5 →